Comparative Effectiveness and Clinical Outcomes Research Center (CECORC)

Clinical Trials at CECORC 

CECORC is currently participating in a number of clinical trials. 

If you are interested in being part of a research clinical trial at RUHS Medical Center, please contact us at CECORC@ruhealth.org. 

Clinical Trials Active – 2020 - 2021 

Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (Novo Nordisk) 

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People with Type 2 Diabetes (Novo Nordisk) 

The Effect of Tirzepatide versus Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes (Eli Lilly and Company) 

Prospective, Open-label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor who Require Urgent Surgery (ANNEXA-S), enrolling early 2021 (Portola Pharmaceuticals) 

Clinical Trials Completed – 2019 

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs (Novo Nordisk) 

Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (GlaxoSmithKline) 

A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of study medication in subjects with active ulcerative colitis (GlaxoSmithKline)